Protocol Ledger

NCT04116502 · Phase III · RECRUITING

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Interventional Phase III clinical trial protocol NCT04116502 sponsored by University of Birmingham in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-25 Enrollment: 586 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04116502
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)586 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04116502
Protocol FieldVerified Registry Value
NCT IdentifierNCT04116502
Consolidated Lead SponsorUniversity of Birmingham
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment586 participants (ESTIMATED)
Registered Start Date2019-10-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04116502
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI